VT3989 is an innovative small molecule drug designed to inhibit TEAD autopalmitoylation within the Hippo signaling pathway. This mechanism aims to counteract the effects of pathway dysregulation that can lead to tumorigenesis, particularly in cancers like mesothelioma and other solid tumors characterized by NF2 mutations.